Dibenzepin

Dibenzepin

Dibenzepin is a tricyclic antidepressant (TCA) that was introduced in Europe in the 1960s for the treatment of depression. It is a member of the dibenzazepine group of compounds and is structurally related to other TCAs such as imipramine and desipramine.

Pharmacology

Dibenzepin acts by inhibiting the reuptake of serotonin and norepinephrine, two neurotransmitters that are involved in mood regulation. This increases the concentration of these neurotransmitters in the synaptic cleft, enhancing their effects and helping to alleviate symptoms of depression.

Clinical Use

Dibenzepin is used primarily in the treatment of major depressive disorder. It may also be used off-label for the treatment of anxiety disorders and certain types of chronic pain. Like other TCAs, dibenzepin is typically reserved for patients who have not responded to other treatments due to its potential for side effects and toxicity.

Side Effects

Common side effects of dibenzepin include dry mouth, constipation, urinary retention, and blurred vision. More serious side effects can include cardiac arrhythmias, seizures, and an increased risk of suicide, particularly in young adults and adolescents.

Contraindications

Dibenzepin is contraindicated in patients with a history of cardiac arrhythmias, recent myocardial infarction, or narrow-angle glaucoma. It should also be used with caution in patients with a history of seizures or bipolar disorder.

See Also

• Tricyclic antidepressant
• Serotonin
• Norepinephrine
• Major depressive disorder
• Anxiety disorders
• Chronic pain

‎